Epigenetic transcriptional regulation plays an important role in the life cycle of human papillomaviruses (HPVs) and the carcinogenic progression of anogenital HPV associated lesions. We performed a study designed to assess the methylation status of the HPV-18 genome, specifically of the late L1 gene, the adjacent long control region (LCR), and part of the E6 oncogene in cervical specimens with a range of pathological diagnoses. In asymptomatic infections and infections with precancerous (precursor) lesions, HPV-18 DNA was mostly unmethylated, with the exception of four samples where hypermethylation of L1 was detected. In contrast, L1 sequences were strongly methylated in all cervical carcinomas, while the LCR and E6 remained unmethylated. HeLa cells, derived from a cervical adenocarcinoma, contain chromosomally integrated HPV-18 genomes. We found that L1 is hypermethylated in these cells, while the LCR and E6 are unmethylated. Treatment of HeLa cells with the methylation inhibitor 5-Aza-2′-deoxycytidine (5-Aza-CdR) led to the expected reduction of L1 methylation. After removal of 5-Aza-CdR, L1 methylation resumed and exceeded pretreatment levels. Unexpectedly, the LCR and E6 also became methylated under these conditions, albeit at lower levels than L1. We hypothesize that L1 is preferentially methylated after integration of the HPV genome into the cellular DNA, possibly since linearization prohibits its normal transcription, while the enhancer and promoter may be protected from methylation by transcription factors. Since our data suggest that HPV-18 L1 methylation can only be detected in carcinomas, except in some few precancerous lesions and asymptomatic infections, L1 methylation may constitute a powerful molecular marker for detecting this important step of neoplastic progression.
Introduction
Human papillomaviruses (HPV) are implicated as causative agents in the etiology of cervical cancer (International Agency for Research on Cancer, 1995) . Eighteen HPV types are associated with nearly 100% of all cervical carcinomas, and among these types, HPV-16 and HPV-18 account for approximately two thirds of these malignant lesions worldwide (Munoz et al., 2003) . HPV-18 has been associated with more aggressive forms of cervical intraepithelial neoplasia (Schwartz et al., 2001; Burk et al., 2003) and has a higher prevalence than HPV-16 in adenocarcinomas (Andersson et al., 2001) . In vitro, the oncoproteins of HPV-16 and -18 have similar molecular properties by binding the p53 and pRB tumor suppressor proteins and interfering with their function (Dyson et al., 1989 , Werness et al., 1990 . However, HPV-18 has been found to have an increased potential for the immortalization of epithelial cells (Schlegel et al., 1988) , possibly due to the higher transcriptional activity of its enhancer-promoter system Romanczuk et al., 1991) . In view of these findings and the taxonomically remote relationship of HPV-16 and -18 (de Villiers et al., 2004) , our research pertaining to gene expression Virology 349 (2006) 175 -183 www.elsevier.com/locate/yviro has aimed to investigate consistencies between these two viruses in addition to type-specific molecular and pathological distinctions. For many years, investigations of HPV gene expression have concentrated on the identification of sequence-specific transcription factors (reviewed in Bernard, 2002) . More recently, it has become clear that epigenetic mechanisms, which influence chromatin conformations that favor or repress gene expression, play a major role in modulating HPV transcription (Stünkel and Bernard, 1999; Zhao et al., 1999) . One of several mechanisms that affect chromatin conformation is the methylation of DNA, specifically at cytidine-guanidine (CpG) dinucleotides. Methylated CpG dinucleotides (meCpGs) bind repressors such as MeCP2, which alter the conformation of nucleosomes through their interaction with histone deactylases in a manner unfavorable to transcription (reviewed in Bird, 1992; Goll and Bestor, 2005) . Methylation of the genomes of HPV-1 and the cottontail rabbit PV was observed more than 20 years ago (Burnett and Sleeman, 1984; Sugawara et al., 1983; Wettstein and Stevens, 1983) . It has also been reported that, as would be expected, in vitro methylated HPV-16 genomes are transcriptionally repressed after transfection into cell culture (Rosl et al., 1993) . However, more recently, it was shown that methylation of the DNA of HPV-16 and -18 takes place regularly in vivo in cervical cells, in patients in situ in addition to cell cultures. Present evidence suggests that the genomes of both viruses can become methylated but apparently in different patterns and in somewhat different pathological contexts (Badal et al., 2003 (Badal et al., , 2004 Kim et al., 2003; Van Tine et al., 2004; Kalantari et al., 2004; Wiley et al., 2005) . It raises questions of where and how HPV genomes are recognized by the cellular DNA methylation machinery and about the role of this mechanism during the HPV life cycle and HPV-dependent carcinogenesis.
We previously reported that 10-20% of the CpGs of the long control region (LCR) of HPV-16 DNA are found methylated in asymptomatic infection. Methylation decreases strongly in precursor lesions, while remethylation occurs in high-grade lesions and carcinomas. It exceeds 50% in the case of some CpG dinucleotides within the L1 gene Wiley et al., 2005) . The transition between hypermethylation in asymptomatic infection and hypomethylation in low-grade lesions correlates with evidence that W12 cell cultures with episomal HPV-16 genomes maintain the viral DNA in a hypermethylated state in undifferentiated cells with hypomethylation occurring upon differentiation (Kim et al., 2003) . This finding supports the hypothesis that HPV-16 can be transcriptionally repressed upon infection. In order to initiate the transforming process, it has to become demethylated as has been found in clinical samples and cell cultures (Kim et al., 2003) . In carcinomas, HPV-16 DNA is normally not found in the episomally replicating form but rather is integrated into the cellular DNA (Schwarz et al., 1985; Daniel et al., 1995) . It is probably not surprising that this correlates with increased methylation Wiley et al., 2005) , since DNA integrating into cellular chromosomes is a preferential target for methylation and transcriptional inactivation (Doerfler et al., 2001) per se. Therefore, there may not be a specific recognition of HPV-16 DNA in this scenario. The possibility of a specific recognition mechanism has been proposed, however, leading to the selective activation of a few HPV-16 genomes in each cell for maintenance of the neoplastic state (Van Tine et al., 2004) .
The project reported here aimed to refine our knowledge of the role of methylation in HPV-18. Our findings are based on a strategy in which we purified DNA from clinical samples and cultured cells, bisulfite treated and PCR amplified this DNA, and cloned the product into an E. coli vector for analysis of individual HPV-18 segments. Our investigations of HPV-16 had pointed to the need for this refined approach, as we had learnt that individual samples and even cell lines contain mixtures of differentially methylated HPV-16 genomes Wiley et al., 2005) . Therefore, analyses based entirely on restriction digestions or direct bisulfite sequencing (Badal et al., 2004) do not lead to robust analyses of this phenomenon. The findings of this study taken together with our previous publications suggest that significant differences exist in the epigenetic regulation of HPV-16 and -18 and that L1 methylation could prove to be a powerful biomarker by which to study tumor progression.
Results

Hypomethylation of the HPV-18 L1 gene and the LCR in asymptomatic patients
The objective of our study was to establish the diversity of methylation patterns in the 3′ part of the L1 gene and throughout the LCR into the 5′ part of the E6 gene of HPV-18 covering a segment of about 1.2 kb with 31 CpG dinucleotides serving as potential methylation targets. This was done after bisulfite treatment of sample DNA, which converts cytosine residues into uracils, while not affecting methyl-cytosine residues. PCR converts the uracils into thymine and the methyl-cytosines into cytosine residues, and DNA sequencing of the PCR product allows for the determination of the methylation pattern before treatment. We analyzed five clones from each clinical sample in order to observe any potential heterogeneity between different HPV-18 genomes within individual samples as detected in our analyses of HPV-16 . Since bisulfite treatment precludes the amplification of large DNA segments, we split the 1.2-kb target into three amplicons of approximately equal size, the first correlating with the 3′ part of the L1 gene, the second with the enhancer, the third with the promoter and 5′ end of the E6 gene. Fig. 1A shows the results obtained with eleven DNA extracts from cervical smears diagnosed as pathologically normal. Three and eight of these samples came from Mexican and Brazilian patients, respectively. It was evident that these samples were only very lightly methylated, with meCpGs observed in only 64 of 1671 positions (3.8%). Altogether, 36 out of 55 HPV-18 genomes were completely unmethylated implying they were transcriptionally unaffected. Most of the methylation was evident in only three samples, which accounted for 49 of the 64 meCpGs. One of these samples (top of Fig. 1A ) had 28 meCpGs in the L1 gene, and only a single meCpG in the LCR. The methylation rate was 7.5% (44 meCpGs among 595 CpGs) in L1, 2.8% (14 meCpGs among 492 CpGs) in the enhancer segment, and 1% (6 meCpGs among 594 CpGs) in the promoter segments. This sample and the second one in Fig. 1A with substantial L1 methylation came from the Brazilian cohort, which otherwise contained hypo-and unmethylated samples. We obtained very similar data for 13 other DNA samples from asymptomatic patients of the same two cohorts, although we could not establish complete data sets because of a shortage of DNA (data not shown). We conclude that methylation is generally very light in asymptomatic HPV-18 infections, with occasional sample-specific increases, preferentially occurring in L1. Specifically, five samples were graded as mild dyskaryosis, which equates to a low-grade abnormality/lesion (the uppermost five data groups in Fig. 1B ), and three samples showed "borderline nuclear changes" (equating most closely to ASCUS, i.e., atypical squamous cells of undetermined significance) (the sixth to eighth data group in Fig. 1B) . Four samples were graded as severe dyskaryosis, which equates to a high-grade abnormality/lesion. All of these samples came from patients from Edinburgh. Similar to the findings with pathologically normal samples, HPV-18 was only very lightly methylated in the majority of these precursors. meCpGs were observed in only 77 of a total of 1849 positions (4.0%). Altogether, 33 out of 60 HPV-18 genomes were completely unmethylated and therefore were likely to be unaffected transcriptionally. Most of the methylation was evident in only two samples, which accounted for 57 of the 77 meCpGs. The HPV-18 genomes in these two samples (the ninth and the eleventh sample in Fig. 1B ) had most of the methylation in the L1 gene. It was also interesting to note that the two, heavily methylated genomes, had been extracted from samples that had high-grade abnormalities. Ordered by genomic region, the methylation rate was 8.9% (59 meCpGs among 660 CpGs) in L1, 1.5% (8 meCpGs among 529 CpGs) in the enhancer segment, and 1.5% (10 meCpGs among 660 CpGs) in the promoter segments. We conclude that methylation is generally very light in HPV-18 containing low-grade precursor lesions, with a potential for intense methylation, however, in high-grade lesions.
Hypomethylation of the HPV-18 L1 gene and the LCR in precancerous (precursor) lesions
Hypermethylation of the HPV-18 L1 gene in carcinomas
Fig . 1C shows the results obtained with 14 DNA preparations from cervical squamous carcinomas. Thirteen of these samples came from patients from Norway and one from a patient in Mexico. Fig. 1C clearly depicts the high methylation rate of the HPV-18 L1 gene in all of these samples in contrast to the sporadic methylation in the LCR. Altogether, meCpGs were observed in 647 among a total of 2170 positions (29.8%). Only four of the 70 HPV-18 genomes were completely unmethylated. Ordered by genomic region, the methylation rate was 76.8% (592 meCpGs among 770 CpGs) in L1, 2.7% (17 meCpGs among 630 CpGs) in the enhancer segment, and 4.8% (37 meCpGs among 770 CpGs) in the promoter segments. We conclude that there is a strong bias for methylation of L1 in carcinomas. Figs. 2A to C represent the summary of the methylation patterns observed in clinical samples in form of bar diagrams.
Preferential methylation of the HPV-18 L1 gene in HeLa cells
In order to evaluate the stability of the methylated/ unmethylated state across the L1-LCR junction, we decided to study methylation changes in an HPV-18 containing cancer cell line in the presence and absence of a methylation inhibitor. We have previously reported that in HeLa cells, which contain about 50 chromosomally integrated HPV-18 copies, the L1 gene is methylated, while the LCR is devoid of meCpGs (Badal et al., 2004) . These data were based on two fairly crude techniques, namely digestion with the restriction enzyme McrBC and direct sequencing of PCR amplicons generated after bisulfite modification. Here, we aimed to establish a precise pattern of methylation across the same 31 CpG dinucleotides between the 3′ part of the L1 gene and the 5′ part of E6 that were analyzed in clinical samples. Fig. 3A shows an analysis of three amplicons covering this genomic region, as described above. In the L1 gene, we found 100 meCpGs among 264 CpG dinucleotides, which cumulatively corresponds to an overall methylation rate of 38%. There were only five of 216 CpGs (1.9%) methylated in the enhancer segment and none in the promoter segment.
We considered it unlikely that the methylation discontinuity observed between the 3′ end of L1 and the 5′ part of the LCR observed in HeLa cells and clinical samples could be an artifact occurring during the generation of the two separate amplicons. However, in order to validate this assumption, we created amplicons across this boundary that included CpG residues from the L1 gene as well as some from the 5′ side of the LCR (amplicons Msp7F and R, see Materials and methods section). All amplicons derived from samples with L1 methylation generated by this strategy had the same discontinuity of the methylated state across the positions 7317 or 7122, respectively (data not shown), as evident from Fig. 2A . We conclude that the specific methylation patterns that we observed in this genomic region are not artifacts of primer design or primer position.
The effect of 5-Aza-CdR treatment and withdrawal on HPV-18 L1 methylation in HeLa cells 5-Aza-CdR is an inhibitor of the maintenance DNA methyltransferase DNMT1, and can be used in cell culture to interfere with CpG methylation and to assess its reestablishment after removal of the drug. Here, we attempted to monitor the effects that this drug had on the methylation of HPV-18 L1 sequences, specifically, to observe which genomic regions are targeted after subsequent culture of the HeLa cells in the absence of the drug. Fig. 3B shows that HPV-18 L1 sequences analyzed after growth of HeLa cells in the presence of 5-Aza-CdR exhibited a moderate reduction in the amount of methylated L1 sequences to 28% (75 meCpGs among 264 CpG residues). There were no methylated CpGs in the enhancer and promoter amplicons. After subsequent growth of the 5-Aza-CdR treated cells for 20 days in the absence of this methylation inhibitor, L1 methylation resumed and reached a level of 61% (162 meCpGs among 264 CpG residues), significantly exceeding the pretreatment level of 38% (Fig. 3C ). While the enhancer and promoter had been nearly completely unmethylated in the absence of 5-Aza-CdR, treatment with this drug and its subsequent removal led to an unexpected and surprising de novo methylation of 38 out of 216 CpG residues (17.6%) of the enhancer segment and 122 of 264 CpGs (46%) of the promoter segment, indicating a lack of complete protection from methylation of the LCR, but a maintenance of limited protection of the segment that binds important enhancer factors like AP-1. Fig. 4 summarizes these observations.
Discussion
Research outside the papillomavirus field has led to the theory of an "epigenetic conversation network" involving histone acetylation, histone deacetylation, cytosine methylation, and histone methylation. These reactions covalently modify nucleosomes and DNA and lead either to a transcriptionally competent or silenced chromatin (Fuks, 2005) . Some of these regulatory mechanisms are well established in papillomaviruses: the LCRs of HPV-6, -11, -16, and -18 genomes each contain a silencer recognized by the transcriptional repressors CDP and YY1, which interact with histone deacetylases (HDACs) and thereby repress the enhancer and E6 promoter (Bauknecht et al., 1992; O'Connor et al., 1996 O'Connor et al., , 2000 Pattison et al., 1997; Zhao et al., 1999; Ai et al., 2000) . It is likely that this process links HPV transcription with epithelial differentiation (Stünkel and Bernard, 1999; Ai et al., 2000) . CDP and YY1 also bind histone methyltransferases, leading to methylated histones, association with DNA methyltransferases, and methylated cytosines (Fuks, 2005) . The resulting meCpG residues bind factors such as MeCP2, which repress transcription through interactions with HDACs. While histone methylation has not yet been studied in papillomaviruses, the correlation between the decreasing concentrations of CDP, YY1 (Pattison et al., 1997; Ai et al., 2000) , and HPV-16 DNA methylation (Kim et al., 2003; Kalantari et al., 2004) during epithelial differentiation suggests an involvement of this mechanistic network in the repression of HPV-16 in undifferentiated epithelial cells in vitro and in asymptomatic infections in situ. This model accommodates the data available for HPV-16 (Badal et al., 2003; Kim et al., 2003; Kalantari et al., 2004) , which indicate that methylation targets HPV-16 genomes in basal layers of squamous epithelia, and a balance between methylation and demethylation appears to influence the viral life cycle and decisions between latent and progressing infections.
In contrast, the findings that we report here do not provide evidence for a similar scenario in HPV-18 as we detected only very low methylation, and often none, in the HPV-18 LCR in asymptomatic infections. The small sample size that was available to us precludes a final conclusion that HPV-16 and HPV-18 really do respond differentially to the cellular methylation machinery (potentially in line with their fairly remote relationship), or whether divergence may originate from different cellular contexts, as HPV-18 may preferentially target columnar rather than squamous epithelia. Nevertheless, these discrepancies are surprising in view of the extensive similarities in the transcription biology of HPV-16 and -18, which bind the same transcription activators and repressors and show a similar chromatin structure with specifically positioned nucleosomes (Stünkel and Bernard, 1999) .
In carcinomas, however, HPV-16 and -18 show similarly a preferential methylation of the L1 gene, and the particularly intense methylation of the HPV-18 L1 gene in all carcinomas, exceeding 80% at some CpG positions, is the most intriguing finding of this study. In HPV-16 associated carcinomas the methylation frequency of three CpGs overlapping with L1 was also pronounced but only slightly exceeded 50%. We had reported in a previous paper that the HPV-18 L1 gene is preferentially methylated (Badal et al., 2004) . This latter study included a few cell lines and clinical samples, and was based on restriction digestion and direct sequencing, two techniques with limited resolution. In that past paper, we had reported that methylation was often absent from all parts of the viral genome except L1 (Badal et al., 2004) . In the present study, we have described refined HPV-18 methylation maps, which has led to the observation that preferential methylation of L1 extends through the 3′ part of the L1 gene precisely to position 7122, which is the last CpG within L1, ten nucleotides upstream of the termination codon of this gene. Occasionally methylation extends to position 7317, 185 bp within the LCR. This region is normally referred to as 5′ LCR and does not include sequences relevant for enhancer function, while the enhancer overlaps with the CpG at position 7460 (part of an E2 binding site) and all CpGs 3′ of this position. An explanation for the precise methylation of L1 may be the fact that this gene is unlikely to be transcribed after recombination in the cancerous state, where L1 is located upstream of the viral transcription regulatory elements. However, the LCR is also not transcribed, and one may have to postulate that its hypomethylated state is maintained through interaction with transcription factors.
The striking difference between intense L1 methylation in all carcinomas and lack of L1 methylation in most asymptomatic smears and low-grade precursor lesions suggests that one should explore whether L1 methylation may be a useful biomarker to study carcinogenic progression. It is noteworthy that the only two precursor lesions with intense L1 methylation had been pathologically diagnosed as high-grade lesions, and it is conceivable that they contained an HPV-18 genome in a molecular state indicative of cancer. Our observation of two smears with L1 methylation, which had been pathologically diagnosed as normal, may point to the power of this approach. Intense methylation of HPV-18 L1 may identify cell populations with integrated HPV-18 genomes and therefore with a molecular predisposition toward high-grade lesions or carcinomas and may highlight pathological misdiagnoses. However, we are aware of the alternative that the early-late switch of papillomaviruses may be accompanied by changes of the methylation status of late genes, and it is possible that our analysis may differentiate between HPV-18 infections with expressed or repressed late genes. We are in the process of improving the technical power of the study of HPV-18 methylation by procedures that selectively detected methylated CpGs, such as meCpG-specific amplification primers and methylation-specific molecular beacons included in real-time PCR experiments.
We observed partial demethylation of HPV-18 L1 in HeLa cells under the influence of 5-Aza-CdR, as expected from similar studies of methylated CpGs in cellular chromosomes (Velicescu et al., 2002) . It is striking that a re-methylation pattern at the border of L1 and the LCR flanking the position 7317 becomes reestablished after discontinuation of 5-Aza-CdR treatment. Methylation exceeded 60% at position 7122 and at all CpGs to the 5′ side and was present at 3-20% levels at the eight CpGs to the 3′ side, overlapping with the enhancer.
This observation strengthens the case for L1 as a unique methylation target, as it is apparently selectively recognized subsequent to 5-Aza-CdR treatment. We do not have an explanation for the methylation of LCR segments, particularly at the promoter of HPV-18, under these conditions, which are spared from methylation during the regular culture of HeLa cells. It has been proposed, however, that remethylation after removal of CpGs may show cell type-specific idiosyncrasies due to differential expression of both the de novo methylase DNMT3a and the maintenance methylase DNMT1 (Velicescu et al., 2002) . It is evident from this and previous studies that the concept of "epigenetic conversation" applies to papillomavirus gene regulation, and that continuing studies of HPV genome methylation will likely have considerable impact both Fig. 4 . CpG methylation of the L1 gene, the enhancer, promoter, and the 5′ part of the E6 gene of HPV-18 in HeLa cells and changes during and after treatment with 5-Aza-CdR. Representation of the data of Fig. 2 in form of a bar diagram to visualize the methylation discontinuity across the genomic position 7122 (at the 3′ end of L1) and 7317 (in the 5′ part of the LCR), and de novo hypermethylation of the enhancer and promoter after withdrawal of the methylation inhibitor. The gaps between the L1, enhancer, and promoter groups of CpGs separate three different amplicons, since it is not possible to obtain 1.2-kb amplicons with bisulfite modified DNA due to degradation. Therefore, each horizontal bar is derived from three different HPV-18 genomes as separated by the gaps. The discontinuity of methylation across the positions 7122 and 7317 was confirmed by contiguous amplicons as explained the Materials and methods and Results sections. The number of clones studied in part of Fig. 2B was reduced for economic and not for scientific reasons, as there was no good reason to study the influence of a methylation inhibitor on the demethylated DNA segment.
to the understanding of the HPV life cycle as well as to molecular insight into and diagnosis of cancer progression events.
Materials and methods
Clinical specimens
DNA samples extracted from cervical carcinomas were obtained from an archival collection of tumors maintained at the Department of Pathology, Norwegian Radium Hospital, Oslo, Norway, and from a specimen obtained during a published study on the genomic diversity of HPVs in Monterrey, Mexico . All of these samples had been diagnosed as squamous carcinomas and none as adenocarcinomas, which are frequently associated with HPV-18. DNA extracted from the residual material of normal and abnormal cervical smear preparations was obtained from archival collections established as a result of previous epidemiological studies at the Ludwig Institute for Cancer Research in Sao Paulo, Brazil (L.L.V.), at the Department of Pathology, National Hospital, Oslo, Norway (B.H.), the Royal Infirmary of Edinburgh, Edinburgh, Scotland (H.A.C. and K.C.), and from a collection of samples (Fajardo and Barrera-Saldaña, unpublished) that reconfirmed a recent investigation from Monterrey, Mexico . No patient was sampled for the purpose of the specific research described here. Unfortunately, the fact that only very few laboratories in the world have large collections of HPV-18 positive samples (due to the relatively low prevalence of this virus compared to HPV-16) led to a bias of geographic overrepresentation in some pathological categories. Thirteen out of fourteen cancer samples came from Oslo, and all DNA extracted from abnormal smears (consistent with evidence of precursor lesions) came from Edinburgh. We do not believe, however, that these geographic biases influenced the study outcome, as we found no correlation between methylation state and geographic origin in previously published research on HPV-16 .
Cell culture and DNA preparations
HeLa cells have been derived from a cervical adenocarcinoma and have been well studied to contain approximately 50 HPV-18 copies in several chromosomal loci (Ambros and Karlic, 1987; Mincheva et al., 1987; Popescu et al., 1987; Lazo et al., 1989) . We used a strain of HeLa cells that has been maintained in our laboratory for many years. Although strains of HeLa cells have been cultured separately for many decades, our recent comparison of several HeLa strains did not point to major differences in the composition and epigenetic status of their endogenous HPV-18 genomes (Badal et al., 2004) . HeLa cells were grown in standard DME medium with 10% fetal bovine serum. The methylation inhibitor 5-Aza-2′-deoxycytidine (5-Aza-CdR) was used at a concentration of 1 μM for 3 days. All DNA preparations from HeLa cells and clinical samples were purified with Qiagen genomic tips following protocols suggested by the supplier.
Bisulfite modification
For bisulfite treatment, 50-1000 ng of sample DNA supplemented with 1 μg of salmon sperm DNA in a total volume of 18 μl in water was denatured with 2 μl of 3 M NaOH and incubated at 37°C. After denaturation, 278 μl of 4.8M sodium bisulfite and 2 μl of 100 mM hydroquinone were added with the mixture being incubated in a thermal cycler for 20 cycles of 55°C for 15 min and 95°C for 30 s. The modified DNA was desalted with the QIAquick PCR purification protocol and desulfonated thereafter by adding 5.5 μl of 3M NaOH and 5 μg glycogen prior to 15-min incubation at 37°C. The DNA was precipitated with 5.6 μl of 3 M sodium acetate and 150 μl of 100% ethanol, followed by centrifugation. The pellet was washed with 70% ethanol and dissolved in 30-50 μl TE buffer (10 mM Tris-HCl pH 8, 1 mM EDTA).
Polymerase chain reactions, primers, T/A cloning and DNA sequencing
Since bisulfite-treated DNA is partially degraded, large amplicons cannot be generated, so we divided the HPV-18 segment that we wanted to study into three amplicons between the genomic position 6845-7186, 7282-7747, and 7753-186. The sequences of the primers were designed according to the genomic sequence of HPV-18 (Myers et al., 1994) assuming conversion of all cytosine residues into uracils. The genomic segment 6845-7186 encompassed the 3′ part of the L1 gene and was amplified with the primers Msp6Fa, AATTATTA-GTTTGGTGGATATATAT (position 6845-6869) and Msp6R, AAAACATACAAACACAACAATAAATA (position 7186-7161). The genomic segment 7282-7747 with the 5′ part of the LCR and its center, including the viral enhancer, was amplified with the primers Msp10F, TAAAATATGT-TTTGTGGTTTTGTG (position 7282-7293) and Msp10R, ATAATTATACAAACCAAATATACAATT (position 7747-7721). The genomic segment 7743-186 with the viral replication origin, the E6 promoter and the 5′ part of the E6 gene was amplified with the primers Msp8F TGTTTAA-TATTTTGTTTATTTTTAATATG (position 7753-7781) and Msp8R, TATCTTACAATAAAATATTCAATTCC (position 186-161). In selected samples, we amplified a fourth segment that spanned the border between the 6845-7186 and 7282-7747 amplicons, using the primers Msp7F, AGATTTAGATTAA-TATTTTTTTGGA (position 6986-7010) and Msp7R, AAAT-TAAAATTTACAATAATACCAAC (position 7537-7512).
PCR was carried out in a 25 μl volume containing 0.2 mM of each of the four dNTPs, 10 pmol of each primer, 2 mM MgCl 2 and 1 U of Ampli Taq Gold (Perkin-Elmer). The PCR conditions were 94°C for 1 min, followed by 40 cycles of 94°C for 10 s, 54°C for 30 s, and 68°C for 1 min with a final extension at 68°C for 7 min. The presence of PCR products was verified by agarose gel electrophoresis, and confirmed amplicons were cloned with the TOPO TA cloning kit for sequencing (Invitrogen). Cloned DNAs were sequenced by Big Dye terminator v3.1 Cycle Sequencing (Applied Biosystems).
